Skip to main content

Synaptic weakening and resilience during Alzheimer’s disease

The first change in the brains of patients with Alzheimer’s disease (AD) and the best biomarker of the disease is synaptic loss. We are interested in understanding molecular mechanisms underlying synaptic weakening in the context of AD and finding ways to protect those precious connections against neurodegeneration. Our research should bring essential information about how synapses are affected by AD pathology and might provide novel therapeutic avenues to treat this disease.


Techniques & Approaches

  • AD model mice 
  • Primary neurons and organotypic slices
  • Fluorescence lifetime imaging
  • Immunohistochemistry
  • Biochemical approaches (palmitoylation assay, CoIP)
  • Patch-clamp electrophysiology

Read Our Publications